Abstract:Background: High expression of Stathmin 1 ( STMN1) protein is related to a poor prognosis in various tumors, including breast cancer. In our previous study, a phospho-STMN1 signature was conducted to predict outcomes in adjuvantly treated breast cancer patients. This study aimed to explore the relationship of STMN1 expression with our phospho-STMN1 signature and the prognosis of patients treated with neoadjuvant chemotherapy (NACT). Methods: A retrospective analysis of 116 patients who received NACT in The First Affiliated Hospital of Sun Yat-sen University between December 2008 and March 2016 was conducted. Patients were followed up through telephone once a year until 2022. The levels of STMN1, Ser16, Ser25, Ser38, and Ser63 phosphorylation and GRP78 expression in pre-NACT biopsy specimens from the patients were detected by immunohistochemistry. The recurrence risk score for each patient was calculated using the p-STMN1/ GRP78 model. Clinical and pathological parameters, pathological complete response and objective response rates, and survival data were analyzed. Results: In patients with NACT-treated breast cancer, high levels of STMN1, Ser25 phosphorylation, Ser38 phosphorylation, and GRP78 were related to worse disease-free survival (DFS), as was a high p-STMN1/GRP78 model risk score. In contrast, high Ser16 and Ser63 phosphorylation levels were related to better DFS [p-STMN1/GRP78 model: P=0.002, HR =0.180 (0.061-0.534); STMN1: P=0.001, HR =0.290 (0.147-0.572); Ser16: P=0.036, HR =2.019 (1.049-3.886); Ser25: P=0.013, HR =0.392 (0.188-0.819); Ser38: P=0.001, HR =0.293 (0.153-0.559); Ser63: P=0.006, HR =3.346 (1.407-7.961); GRP78: P=0.010, HR =0.417 (0.214-0.815)]. However, no significant statistical difference was found in the multivariate regression. The relationship between these markers and the therapeutic effect of NACT (pathological complete response and objective response) showed the same tendency with survival. The area under the receiver operating characteristic curve for the p-STMN1/GRP78 model was 0.790 (P=0.001) with sensitivity of 70% and specificity of 74%. Conclusions: The expression and serine phosphorylation status of STMN1 may be beneficial as biomarkers for predicting the prognosis of breast cancer patients treated with NACT. Our p-STMN1/ GRP78 model could become a widely applied signature for assessing the metastatic risk of breast cancer patients, potentially facilitating their individualized management before NACT.

Stathmin 1 Expression Predicts Prognosis and Benefits from Adjuvant Chemotherapy in Patients with Gallbladder Carcinoma.

Downregulation of Stathmin 1 in Human Gallbladder Carcinoma Inhibits Tumor Growth in Vitro and in Vivo.

Tumor and Serum Gamma-Glutamyl Transpeptidase, New Prognostic and Molecular Interpretation of an Old Biomarker in Gastric Cancer

Stathmin and phospho-stathmin protein signature is associated with survival outcomes of breast cancer patients

Overexpression of Stathmin 1 is Associated with Poor Prognosis of Patients with Gastric Cancer

Clinical Significance of Stathmin1 Expression and Epithelial-Mesenchymal Transition in Curatively Resected Gastric Cancer.

The Prognostic Role of a Phospho-Stathmin 1 Signature in Breast Cancer Treated with Neoadjuvant Chemotherapy

Stathmin 1 is a biomarker for diagnosis of microvascular invasion to predict prognosis of early hepatocellular carcinoma

Association Of Stmn1 With Survival In Solid Tumors: A Systematic Review And Meta-Analysis

Stathmin1 Plays Oncogenic Role and is a Target of MicroRNA-223 in Gastric Cancer

Increased Stathmin Correlates with Advanced Stage and Poor Survival of Non-Small Cell Lung Cancer

Prognostic Role of High Stathmin 1 Expression in Patients with Solid Tumors: Evidence from a Meta-Analysis.

B4GALT1 expression predicts prognosis and adjuvant chemotherapy benefits in muscle-invasive bladder cancer patients

Overexpression of Stathminï¿½1 Correlates with Poor Prognosis and Promotes Cell Migration and Proliferation in Oesophageal Squamous Cell Carcinoma

Overexpression of Stathmin 1 Predicts Poor Prognosis and Promotes Cancer Cell Proliferation and Migration in Ovarian Cancer.

Stathmin1 expression is associated with aggressive phenotypes and cancer stem cell marker expression in breast cancer patients

Tumor Stroma-Infiltrating Mast Cells Predict Prognosis and Adjuvant Chemotherapeutic Benefits in Patients with Muscle Invasive Bladder Cancer.

STC1 promotes esophageal squamous cell carcinoma progression and is associated with poor prognosis

Tumor-infiltrating mast cells predict prognosis and gemcitabine-based adjuvant chemotherapeutic benefit in biliary tract cancer patients

Stathmin is a marker of progression and poor prognosis in esophageal carcinoma.

Downregulation of ST3GAL5 is associated with muscle invasion, high grade and a poor prognosis in patients with bladder cancer